-
1 Comment
IGM Biosciences, Inc is currently in a long term uptrend where the price is trading 7.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
IGM Biosciences, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.5% to $-81K since the same quarter in the previous year.
Finally, its free cash flow fell by 132.7% to $-29M since the same quarter in the previous year.
Based on the above factors, IGM Biosciences, Inc gets an overall score of 3/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US4495851085 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Target Price | 1.875 |
|---|---|
| Beta | 0.57 |
| PE Ratio | None |
| Market Cap | 81M |
| Dividend Yield | None |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IGMS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
